Recruiting
Phase 2

Anti-PD1 & Combinations

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Code:

NCT06295159

Conditions

Melanoma Stage III

Melanoma Stage IV

Advanced Melanoma

Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Nivolumab + Relatlimab

Ipilimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute on 2025-06-11.